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Introduction
Chronic kidney disease (CKD) and worsening renal function (WRF) are important prognostic factors both in patients with heart failure (HF) and reduced fraction and in those with preserved ejection fraction (HFREF and HFPEF, respectively).
1,2
However, evidence-based therapies that can worsen renal function, such as renin angiotensin aldosterone system (RAAS) inhibitors, improve outcome in HFREF, even in patients with pre-existing CKD. [3] [4] [5] Importantly, new evidence suggests that worsening of renal function during the initiation of a RAAS inhibitor, may not have the same adverse prognostic implications as WRF in other circumstances.
3-6
For patients with HFPEF, data on WRF and outcome are scarce and data on the effect of treatment on the association between WRF and outcome are limited to one retrospective analysis of the I-Preserve trial with irbesartan. 7 In that analysis, WRF during initiation of irbesartan treatment was associated with an increased risk of cardiovascular death or HF hospitalization. This finding contrasts strikingly with those reported previously in studies in HFREF. The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity trials (CHARM) offer another opportunity to investigate the relationship between WRF and outcome in patients with HFPEF, and the effect of treatment with an angiotensin receptor blocker (ARB) on that relationship. Moreover, the same analyses are possible in patients with HFREF who were also enrolled in CHARM, allowing a direct comparison between patients with these two types of chronic HF.
Methods
In the CHARM program patients with symptomatic HF were randomly assigned to either candesartan or placebo. 8, 9 Patients with a left ventricular ejection fraction (LVEF) d 40%
were randomized into CHARM-Alternative (N=2028) if they were intolerant of an angiotensin converting enzyme inhibitor (ACEi) or CHARM-Added (N=2548) if taking an
ACEi. Patients with a LVEF > 40% were enrolled in CHARM-Preserved (N=3023). A key exclusion criterion was a serum creatinine e 265 µmol/L (3 mg/dL). The present analyses were carried out in the 2500 patients with a central laboratory measurement of creatinine at baseline and follow-up (6 weeks, 14 months and 26 months), all of whom were enrolled in North America (See supplementary Table 1 for the number of patients in each of the component trials in the CHARM Programme).
10
For the present analyses, HFPEF was defined as LVEF e 45% (with HFREF defined as LVEF <45%) to reflect more recent definitions of this syndrome and to be consistent with IPreserve. Only patients with a serum creatinine at baseline and at least at the 6 week postrandomization visit were included. All patients gave written informed consent before being enrolled. All participating sites received approval from local ethics committees for the conduct of the study program.
Glomerular Filtration Rate and Worsening Renal Function
Estimated glomerular filtration rate (eGFR, mL/min/1.73m 2 ) was calculated using the simplified Modification of Diet in Renal Disease formula and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). There is no universal definition on WRF, and international guidelines do not agree on the best method in establishing WRF. [11] [12] [13] In this study, WRF was defined as both an absolute increase in serum creatinine of e 26.5 µmol/L (e 0.3 mg/dL) and together with a relative increase in serum creatinine of e 25% between baseline and 6 weeks during the uptitration phase of the CHARM-studies in the chronic outpatient setting. In addition, as sensitivity analyses, we also examined WRF defined as an absolute increase in serum creatinine of e 26.5 µmol/L ora reduction in eGFR of either e 20% or e 30%.
Clinical Outcomes
The primary outcome of each of the CHARM trials was the first occurrence of cardiovascular death or HF hospitalization. Secondary outcomes included all-cause mortality, HF hospitalization, combined endpoint of all-cause mortality or HF hospitalization and a composite of major adverse cardiac events (cardiovascular death, admission to hospital for HF, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularisation).
Statistical Analysis
Data are reported as mean ± standard deviation when normally distributed, as median and interquartile ranges when the distribution was skewed and as frequencies and percentages for categorical variables. Student's t test or Mann-Whitney U tests were used to determine significant differences of variables between patients with and without WRF in both treatment groups, and in patients with HFREF and HFPEF. All patients that received the study treatment were included in this analysis and analysed according their treatment group.
Logistic regression was used to determine odds ratios (OR) for the occurrence of WRF at 6 weeks for candesartan treatment compared with placebo. Change in renal function over time was assessed by repeated analysis mixed effect modelling using unstructured covariance. The variables already reported to be of prognostic value in this CHARM were used in multivariable modelling (age, gender, race, NYHA functional class, smoking status, LVEF, systolic and diastolic blood pressure, heart rate, history of angina, stroke, hypertension, diabetes, myocardial infarction and HF hospitalization, as well as certain medical therapies:
diuretic, ACE-inhibitor, spironolactone, calcium channel blocker, other vasodilators and aspirin) 10 We included a random intercept accounting for possible differences on patient North-America and elsewhere in CHARM have been described previously.
9

Baseline characteristics and Worsening Renal Function
Baseline characteristics, stratified by treatment allocation and development of WRF are presented in Table 1 and stratified for HFREF and HFPEF in Table 2 . There were few differences in baseline characteristics for patients with and without WRF. Examining WRF according to treatment assignment, patients developing WRF in the candesartan group more often received diuretics and beta-blockers, and had lower average hemoglobin levels than those who did not develop WRF.
In the overall CHARM population, WRF developed in 282 (12%) of patients at week 6, and was more common with candesartan than with placebo: odds ratio (OR) 2.44 (1.88-3.19), P < 0.001 ( 
WRF and Clinical Outcome
CHARM-Overall
CHARM HFREF
In patients with HFREF, there was a clear association between the occurrence of WRF and the primary outcome of CV death or HF hospitalization in univariate analysis (HR 1.46, 1.17-1.83, P = 0.001), which persisted after adjustment for other prognostic variables and concomitant therapy ( Figure 1A and Table 4 ). WRF was an independent predictor of this composite outcome in both the placebo and candesartan group, without evidence of interaction. After adjustment for other prognostic variables and concomitant therapy, there was a persisting association between WRF and HF hospitalization in both treatment groups, but not for other outcomes.
CHARM HFPEF
Development of WRF showed the same trend with occurrence of the primary outcome (adjusted HR 1.30, 0.89-1.90), compared with patients with HFREF (P for interaction 0.98).
However, this association did not reach statistical significance in either treatment group, after adjustment for the prespecified prognostic variables and concomitant therapy ( Figure 1B , Table 4 ). Similar results were found secondary outcomes, with the exception of CV death.
For this particular outcome, there was trend towards an interaction (P=0.10) between WRF and treatment; WRF was associated with a higher risk of CV death in patients allocated to candesartan in contrast to WRF that occurred with placebo. There was no significant interaction between treatment, WRF and outcomes on multivariable analysis.
Change in eGFR
For all patients, the mean baseline eGFR at baseline was 71 ± 27 mL/min/1.73m 2 . Overall, estimated GFR decreased by 2.8 mL/min/1.73m 2 /year, to 66 ± 27 mL/min/1. eGFR decreased by -6.4 ± 21 mL/min/1.73m 2 overall. The change in eGFR was more pronounced in the candesartan group -8.9 ± 22 versus -3.9 ± 21 mL/min/1.73m 2 for placebo at 26 months follow up (P < 0.001).). In patients with HFPEF, eGFR decreased by -6.7 ± 21 mL/min/1.73m 2 at 26 months, a decline similar to that observed in the HFREF group (P = 0.91). Patients in the candesartan group showed a greater decrease in eGFR at 26 months: -9.2 ± 21 mL/min/1.73m 2 versus -3.8 ± 20 mL/min/1.73m 2 in the placebo group (P = 0.042).
In both HFREF and HFPEF, using the CKD-EPI instead of sMDRD formula showed similar results. Supplementary table 4 summarizes the change in eGFR across HF phenotypes, randomized candesartan treatment and study periods.
Change in mean arterial pressure and discontinuation rates
The reduction in mean arterial pressure (MAP) at 6 weeks was greater in patients with WRF than in those without (-7.9 ± 12 vs. -2.8 ± 11 mmHg , P < 0.001) and patients in the candesartan group with WRF had greater reductions in MAP than patients with WRF in the placebo group (-9.5 ± 11 vs. -4.4 ± 14 mmHg, P = 0.001). These results were similar in HFREF and HFPEF, although the difference of change in MAP between patients with WRF on either placebo or candesartan in HFPEF was numerically, but not statistically, different.
Permanent discontinuation rates within 6 weeks after the second creatinine measurement were significantly higher in patients with WRF, compared to those without WRF (7 vs 2%, P < 0.001). Similar discontinuation rates were observed before WRF occurred (1 vs 2%, P = 0.36). The findings were similar in HFREF and HFPEF.
Discussion
In the present study, eGFR decreased more with candesartan compared with placebo, and this was similar in HFREF and HFPEF. We found that the incidence of WRF was similar in patients with HFREF and HFPEF, overall and separately within the placebo group and candesartan group. Candesartan was associated with a higher incidence of WRF in both types of HF. Overall WRF was associated with worse clinical outcomes. There was no significant interaction between type of HF (or LVEF on a continuous scale), candesartan treatment, occurrence of WRF and the relationship with outcome.
Change in eGFR and ARB treatment
CKD as defined by a reduced eGFR is frequently present in chronic HFREF and HFPEF patients. 1 While there are plentiful data on baseline CKD in HF (mostly HFREF), there are fewer data on change in eGFR over time. In HF patients that were followed after hospitalization, eGFR decreased 7.0 mL/min/1.73m 2 in the next 18 months.
14 In Val-HeFT, patients in the placebo group had a mean decrease of 2.9 mL/min/1.73m 2 after 36 months. 4 In I-Preserve, the mean change in eGFR over 30 months was 5.0 mL/min/1.73m 2 , which was more pronounced in the irbesartan group. 7 Our results are in alignment with these findings. We found a decrease in 4.0 mL/min/1.73m 2 over 26 months.
In keeping with the results of Val-HeFT and I-Preserve, candesartan treatment led to an early (although small) decline in eGFR. 4, 7 This initial decline in GFR is thought to be due to inhibition of the effect of angiotensin on glomerular efferent arterial tone leading to decreased filtration pressure and decreased GFR. This effect was similar in patients with HFREF and HFPEF. After the initial steep fall in eGFR, there was a subsequent slower decrease in eGFR and this was similar in the placebo and candesartan group. Thus, it seems clear from Val-HeFT, I-Preserve and CHARM that ARBs do not preserve renal function in patients with HFREF or HFPEF in contradistinction to patients with diabetic nephropathy.
15,16
Worsening Renal Function, Outcome and candesartan treatment in HFREF WRF, however defined, is associated with poor clinical outcomes in chronic HF although the data supporting this conclusion come predominantly from studies in patients with HFREF.
2
In SOLVD the incidence of WRF with enalapril was similar to what we found in CHARM.
WRF on enalapril was not associated with worse clinical outcome, in contrast to the placebo group. 3 Similarly, in Val-HeFT, valsartan treatment was associated with an increased frequency of WRF compared with placebo (12.3 vs. 5%, respectively), but the beneficial effect of valsartan over placebo was maintained, even in patients experiencing WRF. extreme. This is supported by a meta-analysis of RAAS inhibitor trials examining the relationship between WRF and outcome which showed that the beneficial effects of these drugs over placebo were maintained, even in the presence of WRF.
6
In CHARM, WRF in patients with HFREF was independently associated with a higher risk of the composite endpoint of CV death or HF hospitalization, and this was primarily attributable to an association with HF Hospitaliations. In SOLVD the increased risk related to WRF (versus no WRF) was greater in the placebo than in the enalapril group for the endpoint of all-cause mortality and HF hospitalization was not assessed.
3
In RALES, EMPHASIS-HF and EPHESUS, WRF seemed to be more strongly associated with HF hospitalization than with all-cause mortality.
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A similar association was seen in HF-REF patients in CHARM, although in the candesartan group the risk of HF hospitalization related to WRF was not increased as much in the candesartan group as in the placebo group. It has been difficult to predict beforehand which patients will experience WRF (and have poor outcome). 2 Also from our present analysis, no specific factors, other than severity of heart failure were significantly associated with the occurrence of WRF, irrespective of outcome and treatment.
Worsening Renal Function, Outcome and candesartan treatment in HFPEF
Only two studies to date have examined the prognostic importance of WRF in patients with HFPEF, and in the largest, an analysis from I-Preserve, the picture was different than in HFREF. 7, 19 In I-Preserve, the risk of WRF was twice as high in patients allocated to irbesartan ( 8 vs. 4%) consistent with what is seen with an ACEi or ARB in HFREF. WRF in the entire study population, irrespective of study drug allocation, was associated with a greater risk of cardiovascular death or HF hospitalization. In contrast to HFREF, WRF in I-Preserve patients allocated to irbesartan was associated with poor clinical outcome, which was even worse compared with WRF that occurred in patients allocated to placebo. In patients with HFPEF in CHARM, WRF also appeared to be associated with worse outcomes although this finding was not statistically significant, possibly due to the relatively small number of patients an events studied. WRF occurring during candesartan treatment in HFPEF patients was associated with a higher risk of CV death, while this relationship was less clear in patients receiving placebo or for other endpoint such as HF hospitalization, which was the predominant association with WRF for HFREF patients. Although this apparent difference could reflect the play of chance, it might also indicate that the consequences of ARB-related WRF are different in patients with HFPEF compared with HFREF. We believe that this hypothesis is possible as WRF in the irbesartan group in I-Preserve was also mainly associated with a higher risk of all-cause death, in contrast to that in the placebo group (multivariable P-value for interaction 0.078). 7 However, in our current analysis when LVEF was examined as a continuous variable, there was no interaction between WRF, treatment and outcome. Therefore, we cannot be sure that patients with HRPEF definitely do differ from those with HFREF, although patients with HFPEF and HFREF are dissimilar not only in relation to ejection fraction, but also in relation to demographics, the pathophysiology of heart failure,and therefore possible also in the relationship between WRF and outcome.
Finally, we know that ACE inhibitors and ARBs do not improve outcomes in HFPEF in contrast to HFREF. 20,21 Therefore, whereas any detrimental effect of RAAS inhibition may be entirely outweighed by benefit in HFREF, this will not be the case in HFPEF.
Clinical Perspective on difference between WRF in HFREF and HFPEF
In HFREF, if WRF develops during RAAS-inhibition, treatment should be continued as RAAS inhibition remains advantageous overall, although the benefit may be attenuated (compared with patients not developing WRF), especially with respect to HF hospitalization. 
Limitations
This was a retrospective analysis of a randomized controlled trial, and therefore these results can only be extrapolated to the general HF population with caution. Not all patients had serum creatinines available, and as such selection bias could have arisen. However, serum We had no data on dose of diuretics, which could have been helpful in determining the association between diuretic use, WRF and clinical outcome. We cannot account for unmeasured confounding from known (such as natriuretic peptides) and unknown variables.
Conclusions
Initiation of candesartan led to an immediate but small reduction in eGFR which was similar in patients with HFREF and HFPEF. Approximately one in eight patients reached the threshold for WRF which also occurred with equal frequency in HFREF and HFPEF. WRF was associated with worse clinical outcomes, particularly HF hospitalization in HFREF, and mortality in HFPEF. This association was observed in both the placebo and candesartan groups although the magnitude of excess risk related to WRF was less in the candesartan group. Overall, observations were similar in patients with both HFREF and HFPEF, although subtle differences for different endpoints in multivariable analysis were observed, suggesting that at least some caution should be exercised in HFPEF patients who develop WRF on ARB therapy.
patients with heart failure and preserved ejection fraction. 
